s*****y
发帖数: 4595 | 1 for first job, i think big pharm is better. it is easier to jump from big
pharm to small pharm later than the opposite. |
|
|
R******d
发帖数: 5739 | 3
small pharms,
pros: u r more visible, promotion faster, learn more knowledge, more stock
options
cons: more demanding, unstable, less resource
big pharm,
pros: more resource, less demanding, bonus, better benefit maybe, stable.
cons: promoted slower, more politics maybe, less visible
if u r new grad, u might want to spend some time working for small pharms
for stock options, when u gets older, higher rank, it would be more
difficult to find a job, move to a big pharm |
|
A*****s
发帖数: 813 | 4 small 2-3 years, jump to big
it's hard to get promoted in big pharm |
|
s*****y
发帖数: 4595 | 5 3 years? better after the first promotion.;p |
|
f***s
发帖数: 533 | 6 you mean Centocor? In fact Centocor is probably the best performing unit of
JnJ's pharma business, the impact of jnj's recent layoff in it's pharma
business is probably the smallest for centocor.
different companies have different management styles, some, like pfizer,
like to do big reorg every a few years, with almost no change in between,
other companies, like jnj, like to have small re-org almost every year.
all. This time Amgen's package is 6 month.
in Santaco (? the spelling may be not co |
|
v******V
发帖数: 314 | 7 ☆─────────────────────────────────────☆
szhu (高级肋骨) 于 (Wed Mar 21 21:07:00 2007) 提到:
自己的一篇旧文。感兴趣的人看看。
美国的制药工业依品牌类型可以分为两大类: 创新药行业 (Brand Pharma)和仿制药行
业 (Generic Pharma). 创新药行业通常规模庞大, 其品牌深入人心, 企业年销售额动
辙几十亿几百亿美元. 国人所熟悉的美国制药企业, 诸如辉瑞(Pfizer), 默克(
Merck)等均属此类. 与此同时, 对于美国制药业的另一分枝, 仿制药行业, 多数国人
可能并不熟悉. 美国的仿制药行业在销售额上与创新药行业不可同日而语, 但仍很可
观. 2003年美国仿制药行业的冠军TEVA, 其年度收入亦将近二十亿美元. 近期以来,
笔者发现越来越多的国内制药企业正试图进入美国仿制药市场. 尽管目前多数从提供原
料药(Active Pharmaceutical Ingredient)入手, 也许在不远的将来会有企业涉足制剂
(Finished Dosage) |
|
s**********r
发帖数: 330 | 8 不容易,至少俺还没见过一个CV是CANDIDATE在农产品INDUSTRY的.你也许有相近的SKILL
SET,但是没有PHARMACEUTICAL的EXPERIENCE,在COMPETITION里不太可能是一个STRONG
CONTENDER.太多CANDIDATES有MATCHING SKILLS,还有PHARMA 或CRO的经验,他们更有优
势.尤其如果你是PHD LEVEL.
另外你在农产品FIELD的EXPERIENCE对PHARMA并没有很大的价值. |
|
G*******h
发帖数: 836 | 9 Are you sure? which department/devision of GSK? As far as I know, at least
in US both pharma and consumer healthcare of GSK set Senior Scientist D2 for
fresh phd. and Senior Scientist D1 for phd with 5 more years post-phd
experience. Principle scientist is C band and is considered as manager level
, usually it asks for phd plus 10+ years experience. 而且很多博士干了十几年
也升不到principle,因为leadership不够。另外pharma要求高一些，通常d2根本不招刚
毕业没有博士后经验的人，至少也得毕业两年以上啊。 |
|
B*******t
发帖数: 135 | 10
hold up就是感觉去石油行业基本上是从头做起。。。。。。这几年的research完全浪
费掉。
那是不是也应该跟老板好好谈一下，老板目前还在帮我找pharma行业的机会，他马上要
去几个pharma公司做talk，还说到时候会帮我联系那边的人。
可是这样做似乎挺伤老板感情的。。。。。。 |
|
o****3
发帖数: 5100 | 11 Normally, when economic goes bad, pharma did well becuase people would
invest money here.
But, the pharma is worse, so you get the picture. |
|
R*s
发帖数: 2041 | 12 GSK这个跟经济没关系，是内部re-org合全球重新规划的结果。
pharma今年一开始情况就不好。 下半年经济这一垮后反而显得phamar行对稳定了。
不过经济继续萧条下去，pharma迟早也要受影响。 |
|
w**z
发帖数: 123 | 13 I don't believe any sizable pharma will do this purposely because of the
huge cost associated with it. Either your method did not pick it up or some
accident(s) associated with the manufacture process.
However, I believe every pharma has a complain center and they should
respond to you. Supposely your complain is recorded (required by regulator). |
|
r***l
发帖数: 298 | 14 Pfizer St. Louis,
Greetings from Pfizer Ann Arbor (Circa 2006)!
Yep, I agree with your perspective and would like to follow up a bit.
The pharma industry is undergoing dramatic and traumatic transformation, at
least partially because of expiration of patents for blockbuster drugs with
insufficient replacement portfolio. While working for a pharma company may
not be a highly exhilarating job, it can certainly prepare you with the
experiences required for your next position. In addition to project |
|
s*****l
发帖数: 1844 | 15 He is not kidding. You are insensitive to the change happening years ago.
P&G announced that they would only licence drugs instead of doing drug
discovery itself. It is well known that many big pharmas' discovery group
has not come out with good compounds in 8-12 years, despite burning millions
of dollars.
Big pharma will focus more on development and commercialization, and reply
more on licensing and co-develop compounds from small companies. The
discovery capability of small companies is m |
|
s*****l
发帖数: 1844 | 16 There are some CEOs that emphasize science, however, many do not!! And this
is the trend.
Also if big pharmas outsource much R&D work, how come they do not cut their
own R&D expense?!
Good luck in Wall St. You will understand better then. All companies are
only tools for them, tools for them to make money. Wall St. do not like big
pharma to spend like crazy but get nothing, and this drives the separation
of discovery and late phase development/commercialization. This is the fact.
I have no ch |
|
b*******e
发帖数: 724 | 17 火啥呀,现在PHARMA里已经没有什么火的JOB了. OUTSOURCE出去又快又便宜. 找几个LAB
做DOSING, 取样,CRO一分析DATA.别向了,PHARMA前期的JOB已经是大势已去,未来5-10年
都不会有太大改关了. |
|
p*******c
发帖数: 2 | 18 Present Challenges and Strategies for Biotechnology and
Pharmaceutical Industry
When: May 15 – 16, 2009
Where: The Learning Center , Temple University Ambler campus
Register Online: www.sapa-gp.org
Agenda: http://www.sapa-gp.org/conf9/program.pdf
Leaders from across biotech and pharma will gather next week for an
educational and inspiring two-day conference.
The conference will explore the big challenges facing our business, emerging
markets, the effects of mergers and acquisitions on pharma a |
|
s********s
发帖数: 579 | 19 Agree, Big pharma很有可能发展成为如VC or PE专门买入小Bio,pharma然后包装推向
市场，用强大的Sales赚钱。 |
|
s********s
发帖数: 579 | 20 Neuro只是压倒big pharma R&D的一根稻草而已。
其实纵观small molecular 可以挖出金子来的target已经很少了，即使搞出点什么，
FDA批不批还两说阿。现在FDA聪明啊，打着为公众健康的旗号，对于任何potential的
blockbuster都是4个字“数据不足”，从新补临床数据。这可苦了big pharma，FDA一
句话，你就得继续往里面加billion.
为什么大家一窝蜂搞oncology,还不是门槛低， FDA也不愿得罪癌症病人团体，反正也
治不好，就是延长2月提高生活质量，批。 |
|
s**********4
发帖数: 82 | 21 it is more realistic that you first get the job, then come here to ask
questions like these. The job market is shrinking and there are tons of
experienced people trying to apply for research scientist position in big
pharmas.
Big pharmas do have better benefits and salaries, and the atmosphere should
be better than start-up companies, but you have to get in first. |
|
k********s
发帖数: 320 | 22 来自主题: Pharmaceutical版 - 药厂的工作 That, I have to say, is your wishful thinking...
Yes, fellow level scientist with no supervisory function is in danger, but
pharmas are actively retaining and hiring people with 3-5 years experience
at all level. At least for major pharmas, entry level openings are rare.
BTW, forget about Merck for now, at least for the next half year or so
hiring will be most likely internally. |
|
s*****l
发帖数: 1844 | 23 Making money from biotech/pharma is much more difficult than making money
from other areas, such as real estate, IT, etc. The main hope for Chinese
biotech/pharma to compete in international market will very much depend on
how much invest and support companies can get from the government. Many
companies only want to sell drugs in China b/c it is much easier to make
money. |
|
s*****l
发帖数: 1844 | 24 Of course difficult to get in big pharma now since most of them are actively
laying off people to cut cose. According to GSK executives, more M&A are
coming, which usually means more layoffs as well.
If you have no other offer, just take the small company offer. Of course it
is risky, but you gain some experience. The trend is that big companies
will spin off research to small companies, academics, or their overseas R&D
site... Pharma industry is the next auto industry if there is no
breakthr... 阅读全帖 |
|
s*****l
发帖数: 1844 | 25 USA pharma/Bio is going down unless there is new breakthrough. I do not
think pharma/bio will recover much even if the overall economy improves.
Just my 2 cents.
Regarding your area, toxicology is better than pharmacology, generally
speaking. |
|
c*******u
发帖数: 88 | 26 The high risk development projects should be undertaken by the academia and
government institutions, not the industry. The industry's strength really is
with their development pipeline, CMC, clinical trials, etc. that can
capitalize on really promising candidates.
What the pharma industry did wrong in the past is that they have spent too
much money raising a huge poor of expensive scientists who simply do the
same work as what they'll be doing in an academic lab - cell biology,
biochemistry, scr... 阅读全帖 |
|
G**********n
发帖数: 973 | 27 我一直觉的jj算Conglomerate 不算pharma；当然了jj的pharma还是很厉害的，比如西
安杨森，强生医疗器械之类的 |
|
d*******0
发帖数: 2248 | 28 借朋友的ID，请各位大牛帮忙分析下两个PHD offer，情况如下：
目前申请PHD program 我有两个offer可以选择，基本上就是药剂和药分的选择，所以
比较纠结。望各位版友给给我点评一下，呵呵：
1. UGA （university of georgia) chemistry department：主要用各种mass，LC-
MS 分析glycprotein. fellowship
优点：
1）他们学校的学生推荐我说如果我可以把bioanalytic做得好的话可以进big pharma
的metabolis department。
2）另外我觉得这样以后即使不进pharmaceutical industry,其他相关领域（食品，
环境，clinical trail）应该也可以做吧。而且分析的工作相对研发来讲压力应该也没
有那么大吧。
缺点：教授本人还有他的research和工业界（尤其是Pharma工业）的联系应该没有
那么强。我打听到他们实验室的学生以前很多进industry的，但是最近两年很少了。
2. University of ... 阅读全帖 |
|
c*******u
发帖数: 88 | 29 lol ... this is based on profits, and as you know global companies won't
count how much profit they earn in a perticular local market, but rather sum
up (profits) from all countries as a whole.
I can see that some joint venture companies such as Xi'an Janssen and
Shanghai BMS who reported their profits. They can only be explained that
their chinese partners own the majority of the shares so indeed these are
domestic companies.
See the link below. Bayer's sale in China has reached 5.3 billion RMB... 阅读全帖 |
|
s*****l
发帖数: 1844 | 30 it is really bad. this year's chinese biopharma meeting is also worse than
last year. many people had lay off experience, and some of them started
their own business, but whether their small business can survive is unknown
yet.
this is just the start of pharma/biotech nightmare, in my opinion. who
knows whether big pharma can come back after their socalled reform. Pfizer
is still a mess... |
|
b******k
发帖数: 2321 | 31 LD是生化phd 在西部一小biotech干 最近刚刚拿了个NIBR,cambridge的研发工作offer
俺来帮忙问问各位觉得novartis/nibr前景如何呀？看各种媒体对big pharma是唱衰声
一片呀 pipeline断了啊 小分子什么的没钱途啦 老是裁员啊什么的。。不知道NIBR相
对来说是比较差还是比较好的呢？从小biotech进big pharma继续做研发工作有前途没？ |
|
s*****l
发帖数: 1844 | 32 Do not agree. Now big pharmas are moving away from small molecules to large
molecules. Organic synthetic chemists are mainly synthesizing small
molecules. Together with outsourcing, pharma/bio does not need so many
chemists.
?: 。不管形式怎么样，有技术在手，你就有口饭吃。 |
|
L******r
发帖数: 522 | 33 Cannot type in Chinese...
Diovan compound patent is US 5,399,578, it doesn't have a corresponding
Chinese patent, which means this compound is not protected in China (
although it's protected in HongKong by HK219996). This can be easily found
out if you know how to use EPO worldwide patent database. Do the number
search and check the worldwide patent in the same patent family.
China was not a viable market for big pharmas 20 years ago so it's quite
common for some old products, the innovato... 阅读全帖 |
|
k********s
发帖数: 320 | 34 Not sure I can follow your logic, are you suggesting that if HR did not
give
him a higher title or even made it 1 tier lower, then with his lower
salary
, lower title and possibly better performance than his peers (if, a very
very BIG if, his peers are all fresh Ph.D.s) since he has 4 years'
experience, then he will likely be promoted very quickly down the road?
If
you really think in that way I do seriously wonder if you are still
working
with a big pharma as of now. I mean, seriously??? In t... 阅读全帖 |
|
k********s
发帖数: 320 | 35 Not sure I can follow your logic, are you suggesting that if HR did not
give
him a higher title or even made it 1 tier lower, then with his lower
salary
, lower title and possibly better performance than his peers (if, a very
very BIG if, his peers are all fresh Ph.D.s) since he has 4 years'
experience, then he will likely be promoted very quickly down the road?
If
you really think in that way I do seriously wonder if you are still
working
with a big pharma as of now. I mean, seriously??? In t... 阅读全帖 |
|
c***a
发帖数: 15 | 36 Ph.D may cost me 7 to 8 years if I do it in part-time, I don't want to lose
my FDA job.
The MS is specialized in Regulatory Affairs, when I decide to go industry,
especially in big pharma's RA department, I think this MS degree should be
more valuable than the Ph.D, although I'm not sure.
anyone knows about a J.D. degree in Pharma? better job security and high pay?
is
in |
|
s*****l
发帖数: 1844 | 37 Check out big pharma patent expire time, current revenue drop is just the
beginning, good thing is they still hv quite some cash, but even now, some
big pharma management r lousy, shifting to large molecule & cut ppl may not
be the solution , new drug in market, discovery breakthrough r critical, not
sure they will come in the near future |
|
s*****l
发帖数: 1844 | 38 The point is that I definitely agree that some people can make 150W RMB, or
24W US$ in China. But Jane is saying that 50% of the people who went back in
2008 are making 150W now. Unbelievable. The fact is that few Chinese in the
USA can become Director or higher in Big Pharma/Big Biotech (disregarding
small companies, or start ups).
Here we are not talking about global pay, the pay in China is higher than
the pay in the USA for 50% of the people who went back in 2008??? Honestly,
few Chinese i... 阅读全帖 |
|
P**********e
发帖数: 2 | 39 Multiple Positions Available:
1) Director of Chemistry
A large CRO company is looking for a Director of Chemistry/Site Manager.
This individual will lead and manage medicinal/process chemistry research
activities, coordinate with big-pharma clients, and communicate with the
company headquarter. This position is located in Midwest USA. Some
international travel will be required.
Qualifications:
The ideal candidate will be an energetic individual with a Ph.D. degree in
Organic or Medicina... 阅读全帖 |
|
t***s
发帖数: 163 | 40 【 以下文字转载自 Biology 讨论区 】
发信人: tonys (基因决定人生), 信区: Biology
标 题: Re: 2012-05-12 饶毅座谈会(NYC Cornell)概要与评论－－对Soya
发信站: BBS 未名空间站 (Sat May 26 17:40:08 2012, 美东)
实在没忍住，上来吐槽一下：
1. 饶毅不懂新药研发的规律period。新药研发和基础研究是两回事，饶毅说的“新药
研究”实际上是早期研究，或者临床前研究。R&D投入最大的不是R，而是D。临床试验
，中试放大，质量控制，都需要大量的投资和长年的经验积累。抛开D，光讲R，国内的
投资也差的远呢。不信去查查Genentech，Amgen每年花多少钱做早期研究，项目的深度
广度都是国内没法比的。
2. 美国制药公司的R&D模式已经证明失败了，失败的原因是多方面的，Nature Drug
Discovery有过篇文章给这个问题把脉。FDA监管，华尔街短视，都挤到少数适应症等等
，其中很重要的问题是对疾病了解不足。现在的关键是通过系统生物学的方法理解疾病
，这又需要巨大的投资。整个领域正在期待... 阅读全帖 |
|
M******A
发帖数: 15 | 41 Title: Oncology Physician
Location: Shanghai, China
Company: A Pharma company R&D Center
We are looking for an Oncology Physician for a Pharma company R&D Center in
Shanghai, Below is the detail requirements for the qualified candidate:
POSITION SUMMARY:
The Project Physician is part of the Compound Development Team, providing
oversight and execution of early development program from clinical study
design, protocol development, safety and efficacy data analysis and
interpretation and clinical st... 阅读全帖 |
|
a**********i
发帖数: 48 | 42 CPC Scientific is a world-leading CMO (Contract Manufacturing Organization)
and CRO (Contract Research Organization) of proprietary and generic GMP, non
-GMP peptides and medical devices, serving customers of the pharmaceutical,
biotech, diagnostic, cosmetic, and other industries and academia.
We have a cGMP peptide facility in China which is the only non-US and non-
European facility approved by the US FDA, certified by ISO9001:2000 and
ISO13485. Additionally, we have the largest research pepti... 阅读全帖 |
|
B******y
发帖数: 9065 | 43 哦，难怪我看到几乎所有的Pipeline都从Abbott转到Abbvie去了，如果是整个Pharma部
门都转的话。不过Abbott的Medical Device很Profitable么，貌似还比不上Pharma，这
样分出去其实划不来呀。还有，现在Abbott和Abbvie到底谁更大一些？Abbvie到底有没
有前景，值得一试么？ |
|
s********s
发帖数: 579 | 44 日本人终于收不了Ranbaxy了，把它卖给了一个印度企业Sun Pharma
Sun Pharmaceutical announced Monday a definitive agreement to acquire
Ranbaxy Laboratories under an all-share deal valued at approximately $3.2
billion. Daiichi Sankyo, which currently owns 63.4 percent of Ranbaxy, has
agreed to back the transaction and will hold an about 9 percent stake in the
merged company with the right to nominate one director to Sun Pharma's
board
一个日本的分析师说的很好啊：他们(第一三共）输了全部，损失了40亿美元
"Financially they’ve lost everything – up to $4 bill... 阅读全帖 |
|
a*******r
发帖数: 43 | 45 背景是分析化学PhD，做小分子质谱的。PhD毕业有两个offer，犹豫中，请大家指点迷
津，谢谢大家！
1. 大仪器公司的Software test。好处是工作轻松稳定，以后既可以转仪器公司的
scientist职位，也可以转去做software engineer（但本人没有software背景，需要重
新学习...)。但担心做test久了之后人颓废了，以后再也没法转入Pharma行业。
2. base在药厂的CRO。好处是做大分子质谱，以后有可能留在Pharma行业。坏处是未知
数比较大，药厂很难进...
Salary都不是很好，所以就不在考虑范围内了... |
|
G*g
发帖数: 444 | 46 明显b好 gilead上行
c最烂 这种工作有经验很容易找
a大的pharma不是biotech 上面老板都是pharma的老人 人际关系很复杂 |
|
c********e
发帖数: 598 | 47
。2
If I were you, I would go for software engineering.The bar of pharma
bioinformatics became quite high this year become most spots are filled.In
addition,these professors are looking for jobs in pharma. If you can write
better aligner or
variant calling software, you are welcome. |
|
c********e
发帖数: 598 | 48
。2
If I were you, I would go for software engineering.The bar of pharma
bioinformatics became quite high this year become most spots are filled.In
addition,these professors are looking for jobs in pharma. If you can write
better aligner or
variant calling software, you are welcome. |
|
s******r
发帖数: 868 | 49 但是做的都是Pharma的 项目 Pharma的监管。 难道不是应该很有帮助吗 求不吝赐教
双簧包奉上 |
|
w********g
发帖数: 447 | 50 这个63K的工资有点ridiculous。不如狠狠心，转CS算了。从CRO到转到一个decent的
pharma company还有long way to go。而且就算成功转到pharma去做LC/MS，也就是钱
多点，其他的话也差不太多啦 |
|
